Price Concessionary Bulletin

Overview

The purpose of this bulletin is to present the predicted cost impact of drug price changes, both through the Price Concessions list and also monthly drug tariff (DT) cost variations. The data is calculated by matching the ePACT2 prescribing data for the latest month available to the current prices listed in the NHSBSA Drug Tariff PartVIIIA. An adjustment is also made if necessary to the prescribing data of each drug to account for any difference in dispensing days between the 2 months. Data is presented at region, ICB and SICBL level.

If you have any queries about the content of the report please contact us at nuth.nyrdtc.rxsupp@nhs.net

Frequency

Monthly

Data Period

May 2024 (Drug Tariff), March 2024 (ePACT2 prescribing data)

Monthly Horizon Scanning Report – June 2024

Monthly horizon scanning reports are designed to inform the NHS about new products, significant changes to product licenses, significant new guidance, and decisions that have been made by recognised bodies. 

This information is produced for use by NHS healthcare professionals. 

Drug Tariff Monitor

Overview

The purpose of this report is to present the predicted cost impact of category A, M and C drug tariff PartVIIIA price changes on primary care spending. The data is calculated by matching the ePACT2 prescribing data for the latest month available to the current prices listed in the NHSBSA Drug Tariff PartVIIIA. An adjustment is also made if necessary to the prescribing data of each drug to account for any difference in dispensing days between the 2 months. Data is presented at SICBL and ICB level.

If you have any queries about the content of the report please contact us at nuth.nyrdtc.rxsupp@nhs.net

Frequency

Quarterly

Data Period

April 2024 (Drug Tariff), February 2024 (ePACT2 Prescribing data)

Monthly Horizon Scanning Report – May 2024

Monthly horizon scanning reports are designed to inform the NHS about new products, significant changes to product licenses, significant new guidance, and decisions that have been made by recognised bodies. 

This information is produced for use by NHS healthcare professionals. 

Low priority prescribing – MO opportunities

Overview

This SICBL report is a locality level subsection of the Medicines Optimisation Opportunities Dashboard. It looks at prescribing trends for items and cost, for those items which should not be routinely prescribed in primary care, now termed Low priority prescribing. The NHSE ‘Items which should not be routinely prescribed in primary care’ guidance was originally published in Nov 2017, but has since been updated in 2023. The items and targets presented here reflect the latest guidance update, although a baseline of 2017 is additionally included to demonstrate progress already achieved in this area. ICB, regional and England level data is also included.

If you have any queries about the content of the report please contact us at nuth.nyrdtc.rxsupp@nhs.net

This publication is part of our Strategic Support and Planning contract. To gain access please email us at nuth.nyrdtc.rxsupp@nhs.net.   

Frequency

Quarterly

Data Period

January 2021 to December 2023

Prescribing Update Newsletter – April 2024

Prescribing support newsletters aim to inform readers of work done by the unit and work in progress, to help tailor local work plans and highlight any ‘topical’ issues in prescribing or medicines management.

If you have any suggestions for future topics for the newsletter, then please contact nuth.nyrdtc.rxsupp@nhs.net

This month’s edition focuses on the latest of our Strategic Insights publications “Social Prescribing: Evidence and Outcomes”, and our Medicines in Practice publication “Optimised prescribing of oral iron supplements for iron deficiency anaemia”. It also includes information on some key medicines availability issues, the dates of our upcoming demo and Q&A sessions on RDTC reports, publications, and resources, and another in the series of “Meet the Team” where you can get to know the people behind the work we do.

View the preview below on desktop, or click here to download a copy

Cost Comparison Charts

Overview

The charts included within this report are organised by BNF classification (legacy) and show comparative costs at the NHS basic price1,2 (as of April 2024) for selected agents. Except where indicated otherwise, each chart shows the cost of 1 year3 of treatment at a commonly prescribed daily dose (shown in brackets). The doses given are not intended to imply therapeutic equivalence and for some BNF sub-classifications, such as angiotensin converting enzyme inhibitors (ACE inhibitors), the doses may vary according to indication. Additionally, in some therapeutic areas, for instance antibacterial drugs, the duration of treatment may differ from that shown. Primarily, this report focuses on costs related to prescribing in adults. There are however a few exceptions where products specifically for use in children are represented, such as in the emollient and Infant formulas sections.  Additional notes to highlight any relevant cost related information are also added where appropriate, to improve the clarity of the information presented.

Rationale for inclusion: the cost comparison charts (CCCs) aim to represent the diversity of products available; including the least expensive, most prescribed, higher cost products being prescribed and products with additional features.  The products included are furthermore considered in the context of national and local guidance and stakeholder formulary decisions. It is not possible to represent all pharmaceuticals within these charts.

Stakeholders (under password protection) can access the current version of the CCCs via our website in three formats: PDF, Word and Excel. The Excel version incorporates a more detailed comparison of contraceptives and allows charts to be split by BNF subsections in some instances.

References


1. NHS Business Services Authority (NHS BSA). Drug tariff.

2. NHS BSA. Dictionary of medicines and devices (dM+d).

3. 1 year in this instance is equal to 364 days (rather than 365) standardising 1 month as equal to 28 days.

Time Period

April 2024

Frequency

Quarterly

Monthly Horizon Scanning Report – April 2024

Monthly horizon scanning reports are designed to inform the NHS about new products, significant changes to product licenses, significant new guidance, and decisions that have been made by recognised bodies. 

This information is produced for use by NHS healthcare professionals. 

Prescribing Update Newsletter – March 2024

Prescribing support newsletters aim to inform readers of work done by the unit and work in progress, to help tailor local work plans and highlight any ‘topical’ issues in prescribing or medicines management.

If you have any suggestions for future topics for the newsletter, then please contact nuth.nyrdtc.rxsupp@nhs.net

This month’s edition focuses on recent RDTC publications and the dates of our upcoming demo and Q&A sessions on RDTC reports, publications, and resources.

View the preview below on desktop, or click here to download a copy

Monthly Horizon Scanning Report – March 2024

Monthly horizon scanning reports are designed to inform the NHS about new products, significant changes to product licenses, significant new guidance, and decisions that have been made by recognised bodies. 

This information is produced for use by NHS healthcare professionals.